Drug Profile
ALD 151
Alternative Names: ALD-151; ALDHbr umbilical cord blood cells - AldagenLatest Information Update: 21 Jan 2019
Price :
$50
*
At a glance
- Originator Aldagen
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Haematological malignancies
Most Recent Events
- 21 Jan 2019 DC/MoA project: No updates
- 05 May 2014 Discontinued - Phase-I for Haematological malignancies in USA (IV)
- 08 Feb 2012 Aldagen has been acquired by Cytomedix